PHASE III TRIAL OF MOLNUPIRAVIR IN ADULTS WITH MILD SARS-CoV-2 INFECTION IN INDIA
To improve the management of SARS-Co2 infection there is an urgent unmet need for an orally administered antiviral drug to prevent disease progression, hospitalization, and clinical complications. Molnupiravir was developed in response to this need. This study assesses its efficacy and safety in Indian patients with mild SARS-CoV2 infection. This study is a phase III…